Journal of Skin CancerPub Date : 2015-01-01Epub Date: 2015-01-28DOI: 10.1155/2015/306543
Farahnaz Fatemi Naeini, Bahareh Abtahi-Naeini, Hamidreza Sadeghiyan, Mohammad Ali Nilforoushzadeh, Jamshid Najafian, Mohsen Pourazizi
{"title":"Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study.","authors":"Farahnaz Fatemi Naeini, Bahareh Abtahi-Naeini, Hamidreza Sadeghiyan, Mohammad Ali Nilforoushzadeh, Jamshid Najafian, Mohsen Pourazizi","doi":"10.1155/2015/306543","DOIUrl":"https://doi.org/10.1155/2015/306543","url":null,"abstract":"<p><p>Background. Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma. Extensive studies on Iranian MF patients are absent. The present study aimed to produce updated clinical information on Iranian MF patients. Methods. This was a retrospective, descriptive, single-center study, including all cases of MF seen in the Department of Dermatology, University Hospital of Isfahan, Iran, between 2003 and 2013. Data systematically recorded for each patient included clinical, biological, histological, and molecular findings. Results. Eighty-six patients with clinical and histologic diagnosis of MF were included in the study. Thirty-nine patients (45.3%) were male. Female predominance was observed in patients (male : female ratio is 1 : 1.2). Patients were between 7 and 84 years of age (median: 41). The interval from disease onset to diagnosis ranged from 0 to 55 years (median: 1 year). Eighteen cases (20.9%) had unusual variants of MF. The most common types included hypopigmented and poikilodermatous MF. Childhood cases of MF constituted 5.8% (5/86) of all patients. The early stages were seen in 82 cases (95.34%). Conclusion. The major differences in epidemiologic characteristics of MF in Iran are the lack of male predominance and the lower age of patients at the time of diagnosis. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"306543"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/306543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33065031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2015-01-01Epub Date: 2015-08-12DOI: 10.1155/2015/167847
P T Lekalakala, R A G Khammissa, B Kramer, O A Ayo-Yusuf, J Lemmer, L Feller
{"title":"Oculocutaneous Albinism and Squamous Cell Carcinoma of the Skin of the Head and Neck in Sub-Saharan Africa.","authors":"P T Lekalakala, R A G Khammissa, B Kramer, O A Ayo-Yusuf, J Lemmer, L Feller","doi":"10.1155/2015/167847","DOIUrl":"https://doi.org/10.1155/2015/167847","url":null,"abstract":"<p><p>Oculocutaneous albinism which is characterised by impaired melanin biosynthesis is the most common inherited pigmentary disorder of the skin and it is common among Blacks in sub-Saharan Africa. All albinos are at great risk of developing squamous cell carcinoma of sun-exposed skin, and Black albinos in sub-Saharan Africa are at about a 1000-fold higher risk of developing squamous cell carcinoma of the skin than the general population. In Black albinos, skin carcinoma tends to run an aggressive course and is likely to recur after treatment, very probably because the aetiology and predisposing factors have not changed. Prevention or reduction of occurrence of squamous cell carcinoma of the skin in Black albinos might be achieved through educating the population to increase awareness of the harmful effects of exposure to sunlight and at the same time making available effective screening programs for early detection of premalignant and malignant skin lesions in schools and communities and for early treatment. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"167847"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/167847","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34052251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2015-01-01Epub Date: 2015-06-10DOI: 10.1155/2015/505302
Vanessa Shih, Renske M Ten Ham, Christine T Bui, Dan N Tran, Jie Ting, Leslie Wilson
{"title":"Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis.","authors":"Vanessa Shih, Renske M Ten Ham, Christine T Bui, Dan N Tran, Jie Ting, Leslie Wilson","doi":"10.1155/2015/505302","DOIUrl":"https://doi.org/10.1155/2015/505302","url":null,"abstract":"<p><p>Purpose. Two BRAF(V600E) targeted therapies, dabrafenib and vemurafenib, have received US approval for treatment of metastatic melanoma in BRAF(V600E) patients, a mutation that affects ~50% of patients. We evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for treatment of metastatic melanoma. Methods. A Markov model was developed using a societal perspective. Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine. Costs were obtained from literature, national databases, and Medicare fee schedules. Utilities were obtained from published literature. Deterministic and probabilistic sensitivity analyses were run to test the impact of uncertainties. Results. The incremental cost-effectiveness ratio of dabrafenib was $149,035/QALY compared to dacarbazine. Vemurafenib was dominated by dabrafenib. Probabilistic sensitivity analysis showed that, at a willingness-to-pay (WTP) threshold of ≤$100,000/QALY, dacarbazine was the optimal treatment in ~85% of simulations. At a WTP threshold of ≥$150,000/QALY, dabrafenib was the optimal treatment. Conclusion. Compared with dacarbazine, dabrafenib and vemurafenib were not cost-effective at a willingness-to-pay threshold of $100,000/QALY. Dabrafenib is more efficient compared to vemurafenib. With few treatment options, dabrafenib is an option for qualifying patients if the overall cost of dabrafenib is reduced to $30,000-$31,000 or a WTP threshold of ≥$150,000/QALY is considered. More comparative data is needed. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"505302"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/505302","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34283005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2014-01-01Epub Date: 2014-07-21DOI: 10.1155/2014/284582
Robert M Samstein, Alan L Ho, Nancy Y Lee, Christopher A Barker
{"title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy.","authors":"Robert M Samstein, Alan L Ho, Nancy Y Lee, Christopher A Barker","doi":"10.1155/2014/284582","DOIUrl":"10.1155/2014/284582","url":null,"abstract":"<p><p>Background. Advanced age and immune dysfunction are risk factors for cutaneous squamous cell carcinoma (cSCC) and often render patients with locally-advanced disease medically inoperable or surgically unresectable, but potentially curable with radiotherapy. Concurrent chemotherapy and radiotherapy may not be well tolerated in this population, but another systemic therapy may improve disease control. Objective. Determine the tolerance and efficacy of concurrent cetuximab and radiotherapy (CRT) for patients with locally advanced and unresectable cSCC. Methods. Retrospective analysis of 12 patients treated with CRT for locally advanced and unresectable cSCC. Results. Patients were elderly and 75% had moderate-to-severe comorbidities, while 42% had immune dysfunction. Grades 3-4 adverse events were noted in 83% of patients; 67% required hospital admission for adverse events. Complete and partial response was noted in 36% and 27% (response rate, 64%). Stable and progressive disease was noted in 3 and 1 patients, respectively (disease control rate, 91%). Median progression-free and overall survival were 6.4 and 8.0 months, respectively. Limitations. Retrospective small-cohort, single-institution analysis. Conclusion. Patients selected for CRT were elderly, with comorbidities and immune dysfunction, but treatment responses were observed. Patients selected for this treatment approach have a poor prognosis with limited capacity for therapy; more effective treatment is needed. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"284582"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32596866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2014-01-01Epub Date: 2014-09-17DOI: 10.1155/2014/154340
Melinda B Chu, Jordan B Slutsky, Maulik M Dhandha, Brandon T Beal, Eric S Armbrecht, Ronald J Walker, Mark A Varvares, Scott W Fosko
{"title":"Evaluation of the definitions of \"high-risk\" cutaneous squamous cell carcinoma using the american joint committee on cancer staging criteria and national comprehensive cancer network guidelines.","authors":"Melinda B Chu, Jordan B Slutsky, Maulik M Dhandha, Brandon T Beal, Eric S Armbrecht, Ronald J Walker, Mark A Varvares, Scott W Fosko","doi":"10.1155/2014/154340","DOIUrl":"https://doi.org/10.1155/2014/154340","url":null,"abstract":"<p><p>Recent guidelines from the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) have been proposed for the assessment of \"high-risk\" cutaneous squamous cell carcinomas (cSCCs). Though different in perspective, both guidelines share the common goals of trying to identify \"high-risk\" cSCCs and improving patient outcomes. Thus, in theory, both definitions should identify a similar proportion of \"high-risk\" tumors. We sought to evaluate the AJCC and NCCN definitions of \"high-risk\" cSCCs and to assess their concordance. Methods. A retrospective review of head and neck cSCCs seen by an academic dermatology department from July 2010 to November 2011 was performed. Results. By AJCC criteria, most tumors (n = 211,82.1%) were of Stage 1; 46 tumors (13.9%) were of Stage 2. Almost all were of Stage 2 due to size alone (≥2 cm); one tumor was \"upstaged\" due to \"high-risk features.\" Using the NCCN taxonomy, 231 (87%) of tumors were \"high-risk.\" Discussion. This analysis demonstrates discordance between AJCC and NCCN definitions of \"high-risk\" cSCC. Few cSCCs are of Stage 2 by AJCC criteria, while most are \"high-risk\" by the NCCN guidelines. While the current guidelines represent significant progress, further studies are needed to generate a unified definition of \"high-risk\" cSCC to optimize management. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"154340"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/154340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32741600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A study of Basal cell carcinoma in South asians for risk factor and clinicopathological characterization: a hospital based study.","authors":"Sumir Kumar, Bharat Bhushan Mahajan, Sandeep Kaur, Ashish Yadav, Navtej Singh, Amarbir Singh","doi":"10.1155/2014/173582","DOIUrl":"https://doi.org/10.1155/2014/173582","url":null,"abstract":"<p><p>Objectives. Although the incidence of skin cancers in India (part of South Asia) is low, the absolute number of cases may be significant due to large population. The existing literature on BCC in India is scant. So, this study was done focusing on its epidemiology, risk factors, and clinicopathological aspects. Methods. A hospital based cross-sectional study was conducted in Punjab, North India, from 2011 to 2013. History, examination and histopathological confirmation were done in all the patients visiting skin department with suspected lesions. Results. Out of 36 confirmed cases, 63.9% were females with mean ± SD age being 60.9 ± 14.2 years. Mean duration of disease was 4.7 years. Though there was statistically significant higher sun exposure in males compared to females (P value being 0.000), BCC was commoner in females, explainable by intermittent sun exposure (during household work in the open kitchens) in women. Majority of patients (88.9%) had a single lesion. Head and neck region was involved in 97.2% of cases, with nose being the commonest site (50%) with nodular/noduloulcerative morphology in 77.8% of cases. Pigmentation was evident in 22.2% of cases clinically. Nodular variety was the commonest histopathological variant (77.8%). Conclusions. This study highlights a paradoxically increasing trend of BCC with female preponderance, preferential involvement of nose, and higher percentage of pigmentation in Indians. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"173582"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/173582","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32927533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2014-01-01Epub Date: 2014-05-05DOI: 10.1155/2014/371326
Zhongyun Zhao, Song Wang, Beth L Barber
{"title":"Treatment patterns in patients with metastatic melanoma: a retrospective analysis.","authors":"Zhongyun Zhao, Song Wang, Beth L Barber","doi":"10.1155/2014/371326","DOIUrl":"https://doi.org/10.1155/2014/371326","url":null,"abstract":"<p><p>Objective. To describe treatment patterns and factors influencing treatment in a real-world setting of US patients with metastatic melanoma (MM). Methods. This was a retrospective claims-based study among patients with MM diagnosed between 2005 and 2010 identified from MarketScan databases. Results. Of 2546 MM patients, 66.8% received surgery, 44.7% received radiation, 38.7% received systemic therapies, and 17.7% received all modalities. Patients with lung, brain, liver, or bone metastases were less likely to undergo surgery (all P < 0.0001); patients with lung (P = 0.04), brain (P < 0.001), or liver metastases (P = 0.03) were more likely to receive systemic therapies; patients with brain (P < 0.0001) or bone metastases (P < 0.0001) were more likely to receive radiation therapy. Oncologists were more likely to recommend systemic therapy (P < 0.0001) or radiation (P < 0.0001), while dermatologists were more likely to recommend surgery (P = 0.002). Monotherapy was the dominant systemic therapy (82.4% patients as first-line). Conclusions. Only 39% of MM patients received systemic therapies, perhaps reflecting efficacy and safety limitations of conventional systemic therapies for MM. Among those receiving systemic therapy, monotherapy was the most common approach. Sites of metastases and physician speciality influenced treatment patterns. This study serves as a baseline against which future treatment pattern studies, following approval of new agents, can be compared. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"371326"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/371326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32387173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma.","authors":"Angela Sandru, Eugenia Panaitescu, Silviu Voinea, Madalina Bolovan, Adina Stanciu, Sabin Cinca, Alexandru Blidaru","doi":"10.1155/2014/843214","DOIUrl":"https://doi.org/10.1155/2014/843214","url":null,"abstract":"<p><p>Background. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient's individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective. To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients. Method. Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4 ng/ml was established using the ROC curve. Results. All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4 ng/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period (P = 0.000). The death risk was 12 times higher in pathological MIA group of patients (P = 0.0001). Conclusions. Our data suggest that MIA is an independent prognostic factor for patients with localized CMM. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"843214"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/843214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32520027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2014-01-01Epub Date: 2014-07-20DOI: 10.1155/2014/624143
Sergio Umberto De Marchi, Giuseppe Stinco, Enzo Errichetti, Serena Bonin, Nicola di Meo, Giusto Trevisan
{"title":"The influence of the coexpression of CD4 and CD8 in cutaneous lesions on prognosis of mycosis fungoides: a preliminary study.","authors":"Sergio Umberto De Marchi, Giuseppe Stinco, Enzo Errichetti, Serena Bonin, Nicola di Meo, Giusto Trevisan","doi":"10.1155/2014/624143","DOIUrl":"https://doi.org/10.1155/2014/624143","url":null,"abstract":"<p><p>Background. Although techniques of immunophenotyping have been successful in characterizing the cells in the cutaneous infiltrates of mycosis fungoides little evidence suggests that variations in the phenotypic characterization correlate with prognosis. Objectives. In a preliminary prospective, single-centre, study we correlated the T-cell phenotype in cutaneous biopsies with the progression of the disease to determine whether the coexpression of CD4 and CD8 has an impact on prognosis. Methods. Skin biopsy specimens from 30 newly diagnosed patients were stained with immunoperoxidase techniques to determine their phenotypic characteristics. After a median followup of 42 months patients were divided into two groups with stable and progressive disease. Results. Eighteen patients had the conventional CD4+CD8- T-cell phenotype. Ten patients showed the coexpression of CD4 and CD8 and had a slightly lower rate of progressive disease. Conclusions. The coexpression of CD4 and CD8 in cutaneous lesions is not rare and is associated with a slightly lower rate of progressive disease. Since double positive CD4/CD8 phenotype is rarely reported in mycosis fungoides the presence on conventional immunophenotyping of both CD may be due to a \"mixture\" of neoplastic cells and inflammatory CD8+ tumor infiltrating lymphocytes. Immunohistochemical study combined with confocal microscopy could clarify this issue. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"624143"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/624143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32602862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Skin CancerPub Date : 2014-01-01Epub Date: 2014-02-03DOI: 10.1155/2014/289548
Matthew S Ning, Annette S Kim, Nripesh Prasad, Shawn E Levy, Huiqiu Zhang, Thomas Andl
{"title":"Characterization of the Merkel Cell Carcinoma miRNome.","authors":"Matthew S Ning, Annette S Kim, Nripesh Prasad, Shawn E Levy, Huiqiu Zhang, Thomas Andl","doi":"10.1155/2014/289548","DOIUrl":"https://doi.org/10.1155/2014/289548","url":null,"abstract":"<p><p>MicroRNAs have been implicated in various skin cancers, including melanoma, squamous cell carcinoma, and basal cell carcinoma; however, the expression of microRNAs and their role in Merkel cell carcinoma (MCC) have yet to be explored in depth. To identify microRNAs specific to MCC (MCC-miRs), next-generation sequencing (NGS) of small RNA libraries was performed on different tissue samples including MCCs, other cutaneous tumors, and normal skin. Comparison of the profiles identified several microRNAs upregulated and downregulated in MCC. For validation, their expression was measured via qRT-PCR in a larger group of MCC and in a comparison group of non-MCC cutaneous tumors and normal skin. Eight microRNAs were upregulated in MCC: miR-502-3p, miR-9, miR-7, miR-340, miR-182, miR-190b, miR-873, and miR-183. Three microRNAs were downregulated: miR-3170, miR-125b, and miR-374c. Many of these MCC-miRs, the miR-183/182/96a cistron in particular, have connections to tumorigenic pathways implicated in MCC pathogenesis. In situ hybridization confirmed that the highly expressed MCC-miR, miR-182, is localized within tumor cells. Furthermore, NGS and qRT-PCR reveal that several of these MCC-miRs are highly expressed in the patient-derived MCC cell line, MS-1. These data indicate that we have identified a set of MCC-miRs with important implications for MCC research. </p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"289548"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/289548","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32176417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}